MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-13-2026
Country |
 USA |
IPO year |
1983 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
538 M |
Market Cap[1] |
$ 177 B |
EBITDA (LTM) |
$ 12.4 B |
P/E (LTM) |
26.13 |
P/S (LTM) |
7.03 |
EPS (LTM) |
13.25 |
Amgen is a biopharmaceutical company founded in the USA in 1980. The company is engaged in the development and production of drugs for the treatment of serious diseases such as cancer, rheumatoid arthritis, and osteoporosis.
AMGN is a leading provider of biotechnology products and has over 20,000 employees worldwide. The company has operations in over 100 countries and produces its products in facilities around the world.
The main goal of Amgen is to improve the lives of patients by developing innovative drugs that help fight serious illnesses. The company invests billions of dollars annually in research and development to find new treatment options.
AMGN also advocates for sustainability and environmental protection. The company is committed to reducing its CO2 emissions and making its production processes as environmentally friendly as possible. Amgen is also involved in the community and supports various programs to improve healthcare and education.
Overall, Amgen is an innovative and responsible company dedicated to developing new treatment options for serious illnesses while also striving to protect the environment and support the community.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
BioNTech SE
BNTX
|
$ 97.54 | -5.71 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Burford Capital Limited
BUR
|
$ 5.2 | 5.69 % | $ 820 M | NYSE |  Britain |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | France |
 |
Cerus Corporation
CERS
|
$ 2.72 | 33.99 % | $ 518 M | Nasdaq Global Market | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 21.95 | -2.23 % | $ 3.64 B | Nasdaq Global Select Market,SPB | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market |  Israel |
 |
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | USA |
 |
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | USA |
 |
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
CymaBay Therapeutics
CBAY
|
- | - | $ 3.45 B | Nasdaq Global Select Market | USA |
 |
ChemoCentryx
CCXI
|
- | - | $ 3.74 B | Nasdaq Global Select Market,SPB | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Cardiff Oncology
CRDF
|
$ 1.71 | -1.16 % | $ 114 M | Nasdaq Capital Market | USA |
 |
Caladrius Biosciences
CLBS
|
- | -16.75 % | $ 25.8 M | Nasdaq Capital Market | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
- | - | $ 231 M | Nasdaq Global Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
- | -2.5 % | $ 5.88 M | Nasdaq Capital Market | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
- | - | $ 2.18 B | Nasdaq Global Select Market,SPB | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Editas Medicine
EDIT
|
$ 2.9 | -3.33 % | $ 257 M | Nasdaq Global Select Market,SPB | USA |
 |
Dynavax Technologies Corporation
DVAX
|
- | - | $ 2.02 B | Nasdaq Capital Market | USA |
 |
Edesa Biotech
EDSA
|
$ 17.59 | -3.75 % | $ 56.2 M | Nasdaq Capital Market | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 2.93 | -8.15 % | $ 4.82 M | NYSE American | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
- | -9.21 % | $ 2.55 M | Nasdaq Global Market | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
- | -5.68 % | $ 8.28 M | Nasdaq Global Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Evogene Ltd.
EVGN
|
$ 0.81 | 3.33 % | $ 27.9 M | Nasdaq Global Market | Israel |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | Nasdaq Capital Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.